House Engrossed Senate Bill marijuana; clinical research trials State of Arizona Senate Fifty-seventh Legislature First Regular Session 2025 SENATE BILL 1230 AN ACT Amending section 36-2822, Arizona Revised Statutes; relating to medical marijuana. (TEXT OF BILL BEGINS ON NEXT PAGE)
House Engrossed Senate Bill marijuana; clinical research trials
State of Arizona Senate Fifty-seventh Legislature First Regular Session 2025
SENATE BILL 1230
House Engrossed Senate Bill
marijuana; clinical research trials
State of Arizona
Senate
Fifty-seventh Legislature
First Regular Session
2025
SENATE BILL 1230
AN ACT
Amending section 36-2822, Arizona Revised Statutes; relating to medical marijuana.
(TEXT OF BILL BEGINS ON NEXT PAGE)
Be it enacted by the Legislature of the State of Arizona: Section 1. Subject to the requirements of article IV, part 1, section 1, Constitution of Arizona, section 36-2822, Arizona Revised Statutes, is amended to read: START_STATUTE36-2822. Arizona biomedical research centre; medical marijuana fund; grants; marijuana clinical trials; requirements A. The Arizona biomedical research centre in the department shall provide competitive grants from monies in the medical marijuana fund established by section 36-2817 for marijuana clinical trials that are approved by the United States food and drug administration for evaluating both the safety and efficacy of using marijuana in humans and researching the impacts of marijuana interactions with prescription drugs, nonprescription drugs and illicit drugs. B. Clinical trials funded pursuant to subsection A of this section shall be conducted by Arizona-based researchers from nonprofit organizations or universities, be approved by the United States food and drug administration, the United States drug enforcement administration and an institutional review board and be publishable in peer-reviewed medical and public health journals. The centre shall prioritize randomized controlled clinical trials that study the treatment of autism, epilepsy, post-traumatic stress disorder and pain. C. Notwithstanding title 13, chapter 34, a person who receives a grant for a marijuana clinical trial pursuant to this section and any of the person's employees working on the clinical trial may not be charged with or prosecuted for possession of marijuana that is cultivated for medical use when the person is working on the clinical trial. D. On or before July 1, 2026, the Arizona biomedical research centre may shall provide up to $5,000,000 annually for five consecutive years $2,000,000 from the medical marijuana fund established by section 36-2817 to administer and award competitive grants pursuant to this section. On or before July 1, 2028, the Arizona biomedical research centre shall provide an additional $2,000,000 from the medical marijuana fund established by section 36-2817 to administer and award competitive grants if the department determines the medical marijuana fund has at least two years of operational expenses and will not be at risk of a deficit or require an increase in registry identification card fees. The centre may not use more than five percent of these monies for administrative purposes. END_STATUTE Sec. 2. Requirements for enactment; three-fourths vote Pursuant to article IV, part 1, section 1, Constitution of Arizona, section 36-2822, Arizona Revised Statutes, as amended by this act, is effective only on the affirmative vote of at least three-fourths of the members of each house of the legislature.
Be it enacted by the Legislature of the State of Arizona:
Section 1. Subject to the requirements of article IV, part 1, section 1, Constitution of Arizona, section 36-2822, Arizona Revised Statutes, is amended to read:
START_STATUTE36-2822. Arizona biomedical research centre; medical marijuana fund; grants; marijuana clinical trials; requirements
A. The Arizona biomedical research centre in the department shall provide competitive grants from monies in the medical marijuana fund established by section 36-2817 for marijuana clinical trials that are approved by the United States food and drug administration for evaluating both the safety and efficacy of using marijuana in humans and researching the impacts of marijuana interactions with prescription drugs, nonprescription drugs and illicit drugs.
B. Clinical trials funded pursuant to subsection A of this section shall be conducted by Arizona-based researchers from nonprofit organizations or universities, be approved by the United States food and drug administration, the United States drug enforcement administration and an institutional review board and be publishable in peer-reviewed medical and public health journals. The centre shall prioritize randomized controlled clinical trials that study the treatment of autism, epilepsy, post-traumatic stress disorder and pain.
C. Notwithstanding title 13, chapter 34, a person who receives a grant for a marijuana clinical trial pursuant to this section and any of the person's employees working on the clinical trial may not be charged with or prosecuted for possession of marijuana that is cultivated for medical use when the person is working on the clinical trial.
D. On or before July 1, 2026, the Arizona biomedical research centre may shall provide up to $5,000,000 annually for five consecutive years $2,000,000 from the medical marijuana fund established by section 36-2817 to administer and award competitive grants pursuant to this section. On or before July 1, 2028, the Arizona biomedical research centre shall provide an additional $2,000,000 from the medical marijuana fund established by section 36-2817 to administer and award competitive grants if the department determines the medical marijuana fund has at least two years of operational expenses and will not be at risk of a deficit or require an increase in registry identification card fees. The centre may not use more than five percent of these monies for administrative purposes. END_STATUTE
Sec. 2. Requirements for enactment; three-fourths vote
Pursuant to article IV, part 1, section 1, Constitution of Arizona, section 36-2822, Arizona Revised Statutes, as amended by this act, is effective only on the affirmative vote of at least three-fourths of the members of each house of the legislature.